Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer

Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer
Conditions:   Thyroid Gland Anaplastic Carcinoma;   Thyroid Gland Squamous Cell Carcinoma
Interventions:   Procedure: Conventional Surgery;   Drug: Dabrafenib;   Radiation: Intensity-Modulated Radiation Therapy;   Biological: Pembrolizumab;   Other: Quality-of-Life Assessment;   Drug: Trametinib
Sponsor:   M.D. Anderson Cancer Center
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

July 19, 2022Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments